Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 5, 2001, Pages 459-462

  Rey, David ^a   Schmitt, Marie Paule ^b   Partisani, Marialuisa ^a   Hess Kempf, Georgette ^a   Krantz, Véronique ^a   De Mautort, Erik ^a   Bernard Henry, Claudine ^a   Priester, Michéle ^a   Cheneau, Christine ^a   Lang, Jean Marie ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Efavirenz; Highly active antiretroviral therapy (HAART); Plasma HIV RNA; Protease inhibitors; Side effects

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REBOUND; RECURRENT DISEASE; SIDE EFFECT; VIREMIA; VIRUS LOAD;

EID: 0035880929     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200108150-00006     Document Type: Article

References (22)

1. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel
5. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
6. HIV-protease inhibitors
7. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
8. Lipodystrophy-associated morphological, cholesterol triglyceride abnormalities in a population-based HIV/AIDS treatment
9. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
10. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
11. Maintenance therapy after quadruple induction therapy in HIV-I infected individuals. Amsterdam Duration of Antiretroviral Medication ADAM study
12. A randomized, doubleblind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial
13. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of H1V-1 infection in adults
14. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
15. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
16. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
17. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
18. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
19. Substituting nevirapine for protease inhibitors because of intolerance
20. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
21. Substitution of a nonnucleoside reverse trancriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type I RNA
22. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy